Drugs / SYS6005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06958679 | Apr 2025 → Jan 2027 expected | B-cell neoplasm, cancer | CSPC Megalith Biopharmaceutical Co.,Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-12-20 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - SYS6005 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗
The board of directors (the ‘‘Board ’’) of CSPC Pharmaceutical Group Limited (the ‘‘Company ’’, together with its subsidiaries, the ‘‘Group ’’) is pleased to announce that SYS6005 (Antibody-Drug Conjugate) (the ‘‘Product ’’) developed by the Group has obtained clinical trial approva l granted by the National Medical Products Administration of the People ’s Republic of China to conduct clinical trials in China. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-02-19 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT FOR SYS6005 WITH RADIANCE BIOPHARMA irasia.com ↗ |
| 2024-12-20 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - SYS6005 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYS6005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06958679 ↗ |
| Route | Intravenous | “SYS6005 administered via IV infusion” NCT06958679 ↗ |